These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 16806263

  • 1. Attenuation of cardiac dysfunction by a PPAR-alpha agonist is associated with down-regulation of redox-regulated transcription factors.
    Ichihara S, Obata K, Yamada Y, Nagata K, Noda A, Ichihara G, Yamada A, Kato T, Izawa H, Murohara T, Yokota M.
    J Mol Cell Cardiol; 2006 Aug; 41(2):318-29. PubMed ID: 16806263
    [Abstract] [Full Text] [Related]

  • 2. Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factor-kappa-B pathway.
    Ogata T, Miyauchi T, Sakai S, Takanashi M, Irukayama-Tomobe Y, Yamaguchi I.
    J Am Coll Cardiol; 2004 Apr 21; 43(8):1481-8. PubMed ID: 15093887
    [Abstract] [Full Text] [Related]

  • 3. Endothelin-1-induced cardiac hypertrophy is inhibited by activation of peroxisome proliferator-activated receptor-alpha partly via blockade of c-Jun NH2-terminal kinase pathway.
    Irukayama-Tomobe Y, Miyauchi T, Sakai S, Kasuya Y, Ogata T, Takanashi M, Iemitsu M, Sudo T, Goto K, Yamaguchi I.
    Circulation; 2004 Feb 24; 109(7):904-10. PubMed ID: 14967736
    [Abstract] [Full Text] [Related]

  • 4. PPAR alpha activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats.
    Diep QN, Benkirane K, Amiri F, Cohn JS, Endemann D, Schiffrin EL.
    J Mol Cell Cardiol; 2004 Feb 24; 36(2):295-304. PubMed ID: 14871557
    [Abstract] [Full Text] [Related]

  • 5. Activation of peroxisome proliferator-activated receptor-alpha by fenofibrate prevents myocardial dysfunction during endotoxemia in rats.
    Jozefowicz E, Brisson H, Rozenberg S, Mebazaa A, Gelé P, Callebert J, Lebuffe G, Vallet B, Bordet R, Tavernier B.
    Crit Care Med; 2007 Mar 24; 35(3):856-63. PubMed ID: 17255874
    [Abstract] [Full Text] [Related]

  • 6. PPARalpha activators upregulate eNOS activity and inhibit cytokine-induced NF-kappaB activation through AMP-activated protein kinase activation.
    Okayasu T, Tomizawa A, Suzuki K, Manaka K, Hattori Y.
    Life Sci; 2008 Apr 09; 82(15-16):884-91. PubMed ID: 18346759
    [Abstract] [Full Text] [Related]

  • 7. Chronic activation of peroxisome proliferator-activated receptor-alpha with fenofibrate prevents alterations in cardiac metabolic phenotype without changing the onset of decompensation in pacing-induced heart failure.
    Labinskyy V, Bellomo M, Chandler MP, Young ME, Lionetti V, Qanud K, Bigazzi F, Sampietro T, Stanley WC, Recchia FA.
    J Pharmacol Exp Ther; 2007 Apr 09; 321(1):165-71. PubMed ID: 17215446
    [Abstract] [Full Text] [Related]

  • 8. The PPARalpha activator fenofibrate slows down the progression of the left ventricular dysfunction in porcine tachycardia-induced cardiomyopathy.
    Brigadeau F, Gelé P, Wibaux M, Marquié C, Martin-Nizard F, Torpier G, Fruchart JC, Staels B, Duriez P, Lacroix D.
    J Cardiovasc Pharmacol; 2007 Jun 09; 49(6):408-15. PubMed ID: 17577106
    [Abstract] [Full Text] [Related]

  • 9. Ameliorative effect of combination of fenofibrate and rosiglitazone in pressure overload-induced cardiac hypertrophy in rats.
    Rose M, Balakumar P, Singh M.
    Pharmacology; 2007 Jun 09; 80(2-3):177-84. PubMed ID: 17570955
    [Abstract] [Full Text] [Related]

  • 10. Aspirin and PPAR-alpha activators inhibit monocyte chemoattractant protein-1 expression induced by high glucose concentration in human endothelial cells.
    Dragomir E, Tircol M, Manduteanu I, Voinea M, Simionescu M.
    Vascul Pharmacol; 2006 Jun 09; 44(6):440-9. PubMed ID: 16600694
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Peroxisome proliferator-activated receptor alpha activation decreases metastatic potential of melanoma cells in vitro via down-regulation of Akt.
    Grabacka M, Plonka PM, Urbanska K, Reiss K.
    Clin Cancer Res; 2006 May 15; 12(10):3028-36. PubMed ID: 16707598
    [Abstract] [Full Text] [Related]

  • 14. Effects of simvastatin on the development of the atrial fibrillation substrate in dogs with congestive heart failure.
    Shiroshita-Takeshita A, Brundel BJ, Burstein B, Leung TK, Mitamura H, Ogawa S, Nattel S.
    Cardiovasc Res; 2007 Apr 01; 74(1):75-84. PubMed ID: 17270161
    [Abstract] [Full Text] [Related]

  • 15. Biochemical mechanism of insulin sensitization, lipid modulation and anti-atherogenic potential of PPAR alpha/gamma dual agonist: Ragaglitazar.
    Sharma S, Sowjanya A, Kumari M, Suryaprakash R, Cynthia G, Suresh J, Chakrabarti R.
    Life Sci; 2006 Dec 23; 80(3):235-44. PubMed ID: 17014868
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Antinociceptive and antiedematogenic activities of fenofibrate, an agonist of PPAR alpha, and pioglitazone, an agonist of PPAR gamma.
    Oliveira AC, Bertollo CM, Rocha LT, Nascimento EB, Costa KA, Coelho MM.
    Eur J Pharmacol; 2007 Apr 30; 561(1-3):194-201. PubMed ID: 17343847
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Pravastatin increases survival and suppresses an increase in myocardial matrix metalloproteinase activity in a rat model of heart failure.
    Ichihara S, Noda A, Nagata K, Obata K, Xu J, Ichihara G, Oikawa S, Kawanishi S, Yamada Y, Yokota M.
    Cardiovasc Res; 2006 Feb 15; 69(3):726-35. PubMed ID: 16165109
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.